Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wake Forest University |
---|---|
Information provided by: | Wake Forest University |
ClinicalTrials.gov Identifier: | NCT00696488 |
The purpose of this research study is to see the effectiveness of the study drug for the treatment of actinic keratoses. The study drug is 5-Fluorouracil (Carac®); it will be used in this study to treat your actinic keratoses on your face and anterior scalp.
Condition | Intervention | Phase |
---|---|---|
Actinic Keratosis |
Drug: Fluorouracil 0.5% |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population |
Enrollment: | 20 |
Study Start Date: | April 2007 |
Study Completion Date: | October 2008 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, North Carolina | |
Wake Forest University Health Sciences Dermatology | |
Winston Salem, North Carolina, United States, 27157 |
Principal Investigator: | Steve Feldman, MD, PhD | Wake Forest University |
Responsible Party: | Wake Forest University Health Sciences ( Steve Feldman, MD PhD ) |
Study ID Numbers: | 00000156, 31358 |
Study First Received: | June 9, 2008 |
Last Updated: | February 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00696488 History of Changes |
Health Authority: | United States: Institutional Review Board |
Antimetabolites Keratosis Immunologic Factors Skin Diseases |
Fluorouracil Immunosuppressive Agents Tylosis |
Antimetabolites Antimetabolites, Antineoplastic Keratosis Immunologic Factors Molecular Mechanisms of Pharmacological Action Skin Diseases |
Antineoplastic Agents Therapeutic Uses Fluorouracil Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |